1 completed, 1 terminated. 2 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Terminated 1 |
| Phase 3 | 2 | Completed 1, Terminated 1 |
Follow Activated PI3K-delta Syndrome: new trials by email Literature Review of Activated PI3K-delta Syndrome trials Research Report on Activated PI3K-delta Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Extension to the Study of Efficacy of CDZ173 in Patients With APDS/PASLI CDZ173 - Activated PI3Kdelta Syndrome (APDS); PASLI Disease | Phase 2 / Phase 3 | Terminated | Pharming Technologies B.V. | 37 | 2016-09-08 | 2026-03-30 |
| Study of Efficacy of CDZ173 in Patients With APDS/PASLI CDZ173, Placebo - Common Variable Immunodeficiency (CVID), APDS / PASLI | Phase 2 / Phase 3 | Completed | Novartis Pharmaceuticals | 37 | 2015-08-24 | 2022-08-10 |
Common Variable Immunodeficiency (1) · Immunologic Deficiency Syndromes (1) · Lymphadenopathy (1)
Immune System Diseases (2) · Hemic and Lymphatic Diseases (1) · Immunologic Deficiency Syndromes (1) · Lymphatic Diseases (1)
leniolisib (2)
Novartis Pharmaceuticals (1) · Pharming Technologies B.V. (1)
Belarus (2) · Czechia (2) · Germany (2) · Italy (2) · Netherlands (2) · Russia (2) · United States (2) · Ireland (1) · United Kingdom (1)
Koneti V Rao, MD (1) · Virgil Dalm, MD (1)
PMID 28972011, PMID 36399712, PMID 37797893, PMID 38593221, PMID 41091701
2014 (1), 2016 (1)